公开(公告)号：DE69940616D1

公开(公告)日：2009-04-30

申请号：DE69940616

申请日：1999-07-19

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O

IPC: C07D277/24 ,  A61K31/425 ,  A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12

Abstract: This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.

公开(公告)号：CZ298188B6

公开(公告)日：2007-07-18

申请号：CZ2001203

申请日：1999-07-19

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL A ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O ,  BAUER PHILIP E ,  ALLEN KIMBERLEY A

IPC: C07D417/12 ,  A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42

Abstract: Popisuje se krystalický polymorf ritonaviru, neboli (2S, 3S, 5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)karbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxykarbonyl)amino)-1,6-difenyl-3-hydroxyhexanu, a zpusoby jeho prípravy.

公开(公告)号：SI1097148T1

公开(公告)日：2004-10-31

申请号：SI9930586

申请日：1999-07-19

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL A ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O ,  BAUER PHILIP E ,  ALLEN KIMBERLY A

IPC: A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12 ,  A61K31/425

Abstract: This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.

公开(公告)号：ES2214038T3

公开(公告)日：2004-09-01

申请号：ES99934143

申请日：1999-07-19

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL A ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O

IPC: A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12 ,  A61K31/425

Abstract: This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.

公开(公告)号：ES2200075T3

公开(公告)日：2004-03-01

申请号：ES96937699

申请日：1996-10-18

Applicant: ABBOTT LAB

Inventor： SALEKI-GERHARDT AZITA ,  KESKE ERNEST R

IPC: A61K9/16 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7048 ,  A61K47/32

Abstract: The present invention provides a process for the aqueous granulation of a macrolide antibiotic which comprises mixing a macrolide antibiotic and a carbomer; wetting the mixture with water; and blending the mixture to allow formation of a macrolide antibiotic-carbomer granule.

公开(公告)号：AU2003254711A1

公开(公告)日：2003-11-13

申请号：AU2003254711

申请日：2003-10-14

Applicant: ABBOTT LAB

Inventor： ALLEN KIMBERLY A ,  BAUER PHILIP E ,  SPIWEK HARRY O ,  PATEL KETAN ,  CHEMBURKAR SANJAY R ,  NARAYANAN BIKSHANDARKOIL A ,  SALEKI-GERHARDT AZITA ,  BAUER JOHN F

IPC: C07D417/00

公开(公告)号：AT241963T

公开(公告)日：2003-06-15

申请号：AT96937699

申请日：1996-10-18

Applicant: ABBOTT LAB

Inventor： SALEKI-GERHARDT AZITA ,  KESKE ERNEST R

IPC: A61K9/16 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7048 ,  A61K47/32

Abstract: The present invention provides a process for the aqueous granulation of a macrolide antibiotic which comprises mixing a macrolide antibiotic and a carbomer; wetting the mixture with water; and blending the mixture to allow formation of a macrolide antibiotic-carbomer granule.

公开(公告)号：NO20010298L

公开(公告)日：2001-01-18

申请号：NO20010298

申请日：2001-01-18

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL A ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O ,  BAUER PHILIP E ,  ALLEN KIMBERLY A

IPC: A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/24 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12 ,  C07D417/00

Abstract: This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.

公开(公告)号：CA2235607A1

公开(公告)日：1997-05-09

申请号：CA2235607

申请日：1996-10-18

Applicant: ABBOTT LAB

Inventor： KESKE ERNEST R ,  SALEKI-GERHARDT AZITA

IPC: A61K9/16 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7048 ,  A61K47/32 ,  A61K31/71 ,  B01J2/00

Abstract: The prevent invention provides a process for the aqueous granulation of a macrolide antibiotic which comprises mixing a macrolide antibiotic and a carbomer; wetting the mixture with water; and blending the mixture to allow formation of a macrolide antibiotic-carbomer granule.

公开(公告)号：HU227540B1

公开(公告)日：2011-08-29

申请号：HU0103823

申请日：1999-07-19

Applicant: ABBOTT LAB

Inventor： BAUER JOHN F ,  SALEKI-GERHARDT AZITA ,  NARAYANAN BIKSHANDARKOIL A ,  CHEMBURKAR SANJAY R ,  PATEL KETAN ,  SPIWEK HARRY O ,  BAUER PHILIP E ,  ALLEN KIMBERLY A

IPC: C07D277/24 ,  A61K31/425 ,  A61K31/426 ,  A61K31/427 ,  A61P31/18 ,  A61P37/04 ,  C07D277/28 ,  C07D277/30 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D417/12

Abstract: This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.